Concord Drugs Quarterly Results
Concord Drugs quarterly results. In Mar 2026, Concord Drugs (CONCORD) reported revenue ₹38 Cr and net profit ₹1 Cr — revenue +280.0% YoY. Review CONCORD P/E ratio to evaluate earnings-based valuation against sector peers.
CONCORD Quarterly Results — Revenue, Profit & EPS Highlights
Concord Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Concord Drugs share price today.
- Revenue of ₹38 Cr in Mar 2026 (+81.0% vs Jun 2026, +280.0% vs Mar 2025)
- Net Profit of ₹1 Cr in Mar 2026 (+0.0% vs Jun 2026)
- EBITDA of ₹2 Cr in Mar 2026 (+0.0% vs Jun 2026)
- Operating Margin of 4.0% in Mar 2026 (-7.0pp vs Jun 2026)
- Earnings Per Share of ₹0.47 in Mar 2026 (-44.7% vs Jun 2026)
Concord Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CONCORD quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 38 | 21 | 10 | 10 | 14 | 81.0% | 280.0% |
| Net Profit (₹ Cr) | 1 | 1 | 0 | 0 | 0 | - | - |
| EBITDA (₹ Cr) | 2 | 2 | 1 | 1 | 1 | - | - |
| EPS (₹) | 0.47 | 0.85 | 0.19 | 0.04 | 0.12 | - | - |
| Operating Margin (%) | 4.0% | 11.0% | 11.0% | 10.0% | 7.0% | - | - |
CONCORD Share Price Trend — 1-Year Movement Across Quarterly Results
Concord Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check CONCORD company valuation to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CONCORD vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Concord Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1804.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 159.7 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9550.0 | 2,986 | 751 | -5.0% | - | 25.2% | 337.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1159.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 2050.0 | 1,823 | 282 | -10.5% | - | 15.5% | 396.5 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores